Stirling M L, Prescott R J
Lancet. 1979 Apr 14;1(8120):813-4. doi: 10.1016/s0140-6736(79)91328-x.
The minimum effective dose of intermediate factor-VIII concentrate required for the successful home treatment of spontaneous joint bleeds in six haemophiliacs has been investigated in a randomised trial. 207 episodes of bleeding were included. 5 . 7 units/kg controlled 85% of bleeds, but with a dose of 3 .0 units/kg the risk of failure doubled. This lower dose is inadequate for treatment of bleeds other than those regarded subjectively by the patient as mild. The implications of these findings in terms of availability and usage of factor VIII in this centre are discussed.
在一项随机试验中,研究了6名血友病患者在家中成功治疗自发性关节出血所需的中间型凝血因子VIII浓缩剂的最小有效剂量。纳入了207次出血事件。5.7单位/千克可控制85%的出血,但剂量为3.0单位/千克时,治疗失败的风险增加一倍。对于除患者主观认为的轻度出血以外的其他出血,该较低剂量并不足够。讨论了这些研究结果对该中心凝血因子VIII的可获得性和使用的影响。